secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001157523-23-000029
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock updates 2023 pipeline priorities; Phase 3 SMA trial enrollment completion expected in 2023
--------------------------------------------------------------------------------

- Phase 3 SAPPHIRE trial enrollment to complete in 2023; top-line data expected in 2024, potential launch in 2025.
- Cash, cash equivalents and marketable securities ~$315M as of Dec 31, 2022; runway into 2025.
- 36-month TOPAZ extension data expected H1 2023; 90% of patients remain enrolled in long-term extension.
- Preclinical fibrosis and iron-restricted anemia programs advancing toward IND-enabling studies.
- Jay Backstrom appointed President & CEO (Oct 2022); Jing Marantz appointed CMO (Nov 2022).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000115752323000029/0001157523-23-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000115752323000029/a53178569.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer